Neurophth Therapeutics
Neurophth Therapeutics is a Wuhan, China-based clinical-stage gene therapy company developing AAV-based therapies for inherited ophthalmic genetic diseases, with lead candidate NR082 in clinical development and an in-house manufacturing platform, funded by venture capital toward eventual global commercialization.
- Company typePrivate
- Founded2016
- HeadquartersWuhan, China
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Neurophth Therapeutics does
Neurophth Therapeutics is a China-based, clinical-stage gene therapy company headquartered in Wuhan that develops adeno-associated virus (AAV)-based gene therapies for inherited ophthalmic genetic diseases. The company is positioned as China's first gene therapy company dedicated to ophthalmic indications, with its lead clinical-stage candidate NR082 being advanced toward regulatory milestones and a broader pipeline targeting conditions in the hereditary retinal disease space such as retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease, choroideremia, and optic neuropathies. Its core platform combines proprietary AAV gene therapy know-how with an in-house manufacturing and production platform that has been scaled through successive venture funding rounds.
The company is pre-revenue and operates a capital-intensive R&D and clinical development model funded entirely by equity financing to date. Across five disclosed rounds (Angel 2018, Series A 2020 ~$18.4M, Series B 2021 ~$61.9M, Series C 2021 >$60M, Series C+ 2023 ~$95M), Neurophth has raised approximately $235M+ in cumulative venture capital, with the most recent Series C+ led by Yangtze River-CMB International Industry Fund alongside BGI Group, Fosun International, HSG, and other institutional investors. Proceeds are explicitly directed at accelerating NR082 clinical development, expanding the pipeline, and building out manufacturing capacity, in support of the company's stated ambition to become a global leader in ophthalmic gene therapy.
Future revenue mechanics are expected to derive from commercialization of approved ophthalmic gene therapies, likely distributed through specialty ophthalmology hospitals, academic medical centers, and rare-disease treatment networks, supplemented potentially by out-licensing or royalty arrangements on a global basis. End-customers are patients with inherited ophthalmic genetic diseases who currently have limited or no disease-modifying treatment options. The company is led by Founder and Chairman Li Bin, CTOO Dr. Xiao Su, CSO Li Qiutang, and a full CXO bench including dedicated CMO, COO, CTO, and CFO functions, indicating organizational readiness for late-stage clinical execution and eventual commercial scale-up.
Neurophth Therapeutics firmographics
Firmographics- Name
- Neurophth Therapeutics
- Legal name
- Neurophth Therapeutics
- Website
- https://neurophth.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Neurophth Therapeutics is a Wuhan, China-based clinical-stage gene therapy company developing AAV-based therapies for inherited ophthalmic genetic diseases, with lead candidate NR082 in clinical development and an in-house manufacturing platform, funded by venture capital toward eventual global commercialization.
- Ownership category
- akta.pro rank
Neurophth Therapeutics industry classification
Industry- Product category
- Ophthalmic Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Ophthalmology Disorder Therapies (HLAIAIAK)
- akta.pro secondary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
Keywords
Where Neurophth Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Wuhan
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Neurophth Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pre-revenue clinical development: Neurophth is a clinical-stage gene therapy company; no commercial product is on the market. Operating capital is currently provided by equity financing rounds (Series-C over $60M in 2021, Series C+ ~USD 95M / ~CNY 700M in 2023). Future revenue expected from commercialization of approved ophthalmic gene therapies (likely product sales to hospitals/specialty clinics) and/or out-licensing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Pre-commercial: pricing not publicly disclosed |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels2 records
Neurophth Therapeutics product offering
Product offeringCore offering
Neurophth Therapeutics is a clinical-stage gene therapy company developing AAV (adeno-associated virus)-based gene therapies for ophthalmic genetic diseases. Its lead clinical asset is NR082, with an internal manufacturing/production platform supporting a broader pipeline of ophthalmic gene therapies. The company is pre-revenue and advancing candidates through clinical development toward eventual commercialization.
Product overview
Neurophth Therapeutics is a single-product-platform clinical-stage gene therapy company based in Wuhan, China, focused on developing treatments for ophthalmic genetic diseases. Its pipeline centers on adeno-associated virus (AAV)-based gene therapies, with NR082 as the lead clinical-stage candidate. The company is investing in both clinical advancement of NR082 and the build-out of its broader ophthalmic gene therapy pipeline and manufacturing platform, with the stated ambition of becoming a global leader in ophthalmic gene therapy.
Differentiator
Problem solved
Functional benefit
Products and services
- NR082
Quantifiable outcome
- Raised nearly USD 95 million / CNY 700 million in Series C+ round (Aug 2023) led by Yangtze River-CMB International Industry Fund.
- +1 more outcomes
Companies that use Neurophth Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Neurophth Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Neurophth Therapeutics partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights5 records
Neurophth Therapeutics competitors and assessment
Company assessmentDirect peers
- Spark Therapeutics (Roche): Pioneer in ophthalmic gene therapy and developer of Luxturna, the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65 mutation). Acquired by Roche in 2019. Directly comparable to Neurophth as both target inherited ophthalmic conditions with AAV-based gene therapy, though Spark is far more clinically advanced and capitalized.
- Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases including wet AMD and diabetic macular edema. Directly competes with Neurophth in the AAV-ophthalmic space with similar modality and clinical-stage positioning.
- REGENXBIO: Clinical-stage biotech developing AAV gene therapies including RGX-314 for wet AMD (partnered with AbbVie). Comparable to Neurophth as an AAV-platform gene therapy company targeting ophthalmic indications, with a more advanced clinical pipeline and broader therapeutic focus.
- MeiraGTx: Clinical-stage gene therapy company with multiple ophthalmic programs (AAV-RPGR for X-linked retinitis pigmentosa, AAV-CNGA3 for achromatopsia) and in-house AAV manufacturing. Highly comparable to Neurophth in modality, therapeutic focus, and vertically integrated manufacturing strategy.
- GenSight Biologics: Clinical-stage gene therapy company developing AAV-based therapies for rare ophthalmic and neurodegenerative diseases, including LUMEVOQ for Leber Hereditary Optic Neuropathy (LHON) — likely the closest direct competitor to Neurophth's NR082 if it targets the same indication.
- 4D Molecular Therapeutics: Clinical-stage AAV gene therapy company with ophthalmic programs for choroideremia and other inherited retinal diseases. Comparable to Neurophth in modality (custom AAV vectors) and rare ophthalmic disease focus, with a broader therapeutic vector portfolio.
- Applied Genetic Technologies Corp (AGTC): Clinical-stage gene therapy company developing AAV-based therapies for rare inherited retinal diseases including X-linked retinitis pigmentosa and achromatopsia. Directly comparable to Neurophth in therapeutic focus on inherited ophthalmic conditions using AAV delivery.
Emerging players
- ViGeneron: European clinical-stage gene therapy company developing AAV-based therapies for ophthalmic indications including retinitis pigmentosa. Comparable to Neurophth in modality and disease focus, though earlier-stage and focused on the European market.
- Coave Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for rare ophthalmic and CNS diseases. Comparable to Neurophth in modality (AAV platform) and rare disease focus, though with a broader therapeutic footprint including CNS indications.
Broad incumbents
- Biogen: Large diversified biopharmaceutical company with ophthalmic gene therapy programs (notably through its partnership with AGTC for inherited retinal diseases). Relevant comparable as a potential strategic acquirer or partner for Neurophth given Biogen's CNS/ophthalmic franchise and global commercialization reach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Neurophth Therapeutics social profiles
Digital presenceNeurophth Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neurophth Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Neurophth Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neurophth Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neurophth Therapeutics
What does Neurophth Therapeutics do?
Neurophth Therapeutics is a clinical-stage gene therapy company developing AAV (adeno-associated virus)-based gene therapies for ophthalmic genetic diseases. Its lead clinical asset is NR082, with an internal manufacturing/production platform supporting a broader pipeline of ophthalmic gene therapies. The company is pre-revenue and advancing candidates through clinical development toward eventual commercialization.
Is Neurophth Therapeutics a public or private company?
Neurophth Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Neurophth Therapeutics founded?
Neurophth Therapeutics was founded in 2016. It employs 101 to 250 people.
Where is Neurophth Therapeutics based?
Neurophth Therapeutics is headquartered in Wuhan, China, in the Asia region.
How does Neurophth Therapeutics make money?
One revenue line is on record: pre-revenue clinical development.
Who are Neurophth Therapeutics's main competitors?
Direct peers on record are Spark Therapeutics (Roche), Adverum Biotechnologies, REGENXBIO, MeiraGTx, GenSight Biologics, 4D Molecular Therapeutics and Applied Genetic Technologies Corp (AGTC). Emerging players are ViGeneron and Coave Therapeutics. Biogen is listed as a broad incumbent.
Does Neurophth Therapeutics have an API?
No public API is recorded for Neurophth Therapeutics.
What industry is Neurophth Therapeutics in?
Neurophth Therapeutics's product category is Ophthalmic Gene Therapy. Its primary akta.pro industry code is HLAIAIAK, Rare Ophthalmology Disorder Therapies, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 2836.